EVIDENCE OF ONGOING MAST-CELL AND EOSINOPHIL DEGRANULATION IN SYMPTOMATIC ASTHMA AIRWAY
EVIDENCE OF ONGOING MAST-CELL AND EOSINOPHIL DEGRANULATION IN SYMPTOMATIC ASTHMA AIRWAY
复制标题
DOI：
10.1016/0091-6749(91)90158-k
复制
发表时间：
1991-10-01
影响因子：
14.2
通讯作者：
WASSERMAN, SI
中科院分区：
文献类型：
--
作者：
BROIDE, DH;GLEICH, GJ;WASSERMAN, SI
为了评估中度症状性哮喘受试者的气道中是否发生肥大细胞和嗜酸性粒细胞（EOS）脱颗粒，我们测量了肥大细胞衍生介质的水平，（组胺和类胰蛋白酶）和EOS衍生介质从症状性哮喘患者（N = 14）和无症状性哮喘患者（N = 9）获得的支气管肺泡灌洗液（BALF）中的主要碱性蛋白和EOS源性神经毒素非哮喘患者（N = 6）。症状性哮喘患者的FEV 1（1.52 +/- 0.33 L：预计FEV 1的55% +/- 15%）和50%用力呼气流量（FEF 50）（1.11 +/- 0.62 L/sec：预计FEF 50的26% +/- 14%）均显著低于无症状性哮喘患者的相应值FEV 1（3.16 +/- 0.45 L：预计FEV 1的86% +/- 10%）和FEF 50（4.04 +/- 1.54 L/sec：预计FEF 50的71% +/- 25%）。组胺水平（4.8 +/- 5.0 ng/ml vs 0.2 +/- 0.2 ng/ml）（p = 0.05），EOS源性神经毒素（420.6 +/- 959.4 ng/ml vs 12.6 +/- 7.7 ng/ml）（p = 0.05），主要碱性蛋白（31.4 +/- 46.6 ng/ml对比< 9 ng/ml）（p = 0.05），和EOS百分比（10.6% +/- 7.0% vs 1.1% +/- 0.9% BAL细胞）（p = 0.0006）在有症状的哮喘患者与无症状的哮喘患者相比，BALF中均显著升高。与无症状哮喘患者相比，有症状哮喘患者BALF中类胰蛋白酶水平升高（13.2 +/- 14.8 ng/ml vs 3.9 +/- 3.9 ng/ml），接近但未达到统计学显著性。有症状的哮喘患者BAL肥大细胞自发释放组胺的比例为46% +/- 5%，而无症状的哮喘患者为5% +/- 2%。在对抗人IgE的反应中，无症状哮喘患者的BAL肥大细胞组胺释放增加到25% ± 10%，而在有症状哮喘患者的BAL肥大细胞中，没有发生抗IgE增强组胺释放。这项研究表明，肥大细胞和EOS脱颗粒正在进行中的中度症状性哮喘患者的气道。
To assess whether mast cell and eosinophil (EOS) degranulation occurs in the airway of subjects with moderately symptomatic asthma, we have measured levels of performed mast cell-derived mediators (histamine and tryptase) and EOS-derived mediators (major basic protein and EOS-derived neurotoxin) in bronchoalveolar lavage fluid (BALF) obtained from patients with symptomatic (N = 14) and asymptomatic asthma (N = 9) and patients without asthma (N = 6). Both the FEV1 (1.52 +/- 0.33 L:55% +/- 15% of predicted FEV1) and the forced expiratory flow at 50% (FEF50) (1.11 +/- 0.62 L/sec: 26% +/- 14% of predicted FEF50) in the patients with symptomatic asthma were significantly lower than the corresponding values for FEV1 (3.16 +/- 0.45 L:86% +/- 10% of predicted FEV1) and the FEF50 (4.04 +/- 1.54 L/sec:71% +/- 25% of predicted FEF50) in the patients with asymptomatic asthma. Levels of histamine (4.8 +/- 5.0 ng/ml versus 0.2 +/- 0.2 ng/ml) (p = 0.05), EOS-derived neurotoxin (420.6 +/- 959.4 ng/ml versus 12.6 +/- 7.7 ng/ml) (p = 0.05), major basic protein (31.4 +/- 46.6 ng/ml versus < 9 ng/ml) (p = 0.05), and percent EOSs (10.6% +/- 7.0% versus 1.1% +/- 0.9% of BAL cells) (p = 0.0006) were all significantly elevated in BALF from symptomatic compared to asymptomatic patients with asthma. The elevated levels of tryptase (13.2 +/- 14.8 ng/ml versus 3.9 +/- 3.9 ng/ml) in BALF from symptomatic compared to asymptomatic patients with asthma approximated, but did not reach, statistical significance. Spontaneous histamine release from BAL mast cells of symptomatic patients with asthma was 46% +/- 5% compared to 5% +/- 2% in asymptomatic patients with asthma. In response to antihuman IgE, histamine release from BAL mast cells recovered from asymptomatic patients with asthma increased to 25% +/- 10%, whereas in BAL mast cells of symptomatic patients with asthma, no anti-IgE potentiation of histamine release occurred. This study suggests that mast cell and EOS degranulation is ongoing in the airway of patients with moderately symptomatic asthma.